Clinical Observation of Linezolid, Teicoplanin and Vancomycin in the Treatment of Hospital-acquired MRSA Pneumonia
	    		
		   		
		   			
		   		
	    	
    	 
    	10.6039/j.issn.1001-0408.2016.26.35
   		
        
        	
        		- VernacularTitle:利奈唑胺、替考拉宁及万古霉素治疗院内MRSA肺炎的临床观察
 
        	
        	
        	
        		- Author:
	        		
		        		
		        		
			        		Yuefang WANG
			        		
			        		;
		        		
		        		
		        		
			        		Wei ZHONG
			        		
			        		;
		        		
		        		
		        		
			        		Donglin CHEN
			        		
			        		
		        		
		        		
		        		
		        		
		        		
			        		
			        		
		        		
	        		
        		 
        	
        	
        	
        		- Publication Type:Journal Article
 
        	
        	
        		- Keywords:
        			
	        			
	        				
	        				
			        		
				        		Linezolid;
			        		
			        		
			        		
				        		Teicoplanin;
			        		
			        		
			        		
				        		Vancomycin;
			        		
			        		
			        		
				        		Methicillin-resistant Staphylococcus aureus;
			        		
			        		
			        		
				        		Efficacy;
			        		
			        		
			        		
				        		Inflammatory factor
			        		
			        		
	        			
        			
        		
 
        	
            
            
            	- From:
	            		
	            			China Pharmacy
	            		
	            		 2016;27(26):3708-3710
	            	
            	
 
            
            
            	- CountryChina
 
            
            
            	- Language:Chinese
 
            
            
            	- 
		        	Abstract:
			       	
			       		
				        
				        	OBJECTIVE:To observe clinical efficacy and safety of linezolid,teicoplanin and vancomycin in the treatment of hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA). METHODS:120 patients diagnosed as hospital-acquired MRSA pneumonia were divided into linezolid group,teicoplanin group and vancomycin group according to therapeutic regimen,with 40 cases in each group. Linezolid group received Linezolid injection 600 mg,ivgtt,bid;teicoplanin group received Teicoplanin injection 0.4 g,ivgtt,bid;vancomycin group received Vancomycin injection 1 000 mg,bid,ivgtt. 3 groups received 2 weeks of treatment. Clinical efficacy and bacterial clearance effective rate of 3 groups were observed as well as serum levels of inflammatory factors before and after treatment. ADR of 3 groups were compared. RESULTS:The clinical effective rates of linezolid group,teicoplanin group and vancomycin group were 90.0%,72.5% and 67.5%;the effective bacterial clearance rates were 85.0%,60.0% and 57.5%,respectively. The clinical effective rate and the effective bacterial clearance rate in linezolid group were significantly higher than those in teicoplanin group and vancomycin group,with statistical significance (P<0.05). There was no statistical significance in above indexes between teicoplanin group and vancomycin group (P>0.05). There was no statistical significance serum inflammatory factors among 3 groups before treatment (P>0.05). CRP and PCT of 3 groups de-creased significantly after treatment,and those of linezolid group were lower than teicoplanin group and vancomycin group,with statistical significance(P<0.05). There was no statistical significance in serum inflammatory factors between teicoplanin group and vancomycin group before and after treatment (P>0.05). There was no statistical significance in the incidence of ADR among 3 groups (P>0.05). CONCLUSIONS:For hospital-acquired MRSA pneumonia,linezolid is better than teicoplanin and vancomycin in pneumonia control with good safety.